Greenwich LifeSciencesGLSI
About: Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Employees: 8
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
11% more funds holding
Funds holding: 46 [Q1] → 51 (+5) [Q2]
1% more capital invested
Capital invested by funds: $11.1M [Q1] → $11.2M (+$86.1K) [Q2]
0.38% more ownership
Funds ownership: 8.84% [Q1] → 9.21% (+0.38%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for GLSI.
Financial journalist opinion
Based on 4 articles about GLSI published over the past 30 days









